Doxorubicin–Loaded Human Serum Albumin Submicron Particles: Preparation, Characterization and In Vitro Cellular Uptake
Doxorubicin (DOX) is an effective anthracycline antibiotic drug which is commonly used in a broad range cancer therapy. However, due to dose depending side effects and toxicity to non-cancerous tissues, its clinical applications are restricted. To overcome these limitations, human serum albumin (HSA...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-03-01
|
| Series: | Pharmaceutics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1999-4923/12/3/224 |
| _version_ | 1798005546425516032 |
|---|---|
| author | Saranya Chaiwaree Ausanai Prapan Nittiya Suwannasom Tomás Laporte Tanja Neumann Axel Pruß Radostina Georgieva Hans Bäumler |
| author_facet | Saranya Chaiwaree Ausanai Prapan Nittiya Suwannasom Tomás Laporte Tanja Neumann Axel Pruß Radostina Georgieva Hans Bäumler |
| author_sort | Saranya Chaiwaree |
| collection | DOAJ |
| description | Doxorubicin (DOX) is an effective anthracycline antibiotic drug which is commonly used in a broad range cancer therapy. However, due to dose depending side effects and toxicity to non-cancerous tissues, its clinical applications are restricted. To overcome these limitations, human serum albumin (HSA) has been investigated as a biocompatible drug delivery vehicle. In this study, human serum albumin submicron particles (HSA-MPs) were fabricated by using the Co-precipitation–Crosslinking–Dissolution technique (CCD technique) and DOX was loaded into the protein particles by absorption. DOX-HSA-MPs showed uniform peanut-like shape, submicron size and negative zeta-potential (−13 mV). The DOX entrapment efficiency was 25% of the initial amount. The in vitro release in phosphate buffered saline pH 7.4 was less than 1% within 5 h. In contrast, up to 40% of the entrapped DOX was released in presence of a protein digesting enzyme mixture (Pronase<sup>®</sup>) within the same time. In addition, in vitro cytotoxicity and cellular uptake of DOX-HSA-MPs were evaluated using the lung carcinoma cell line A549. The results demonstrated that DOX-HSA-MPs reduced the cell metabolic activities after 72 h. Interestingly, DOX-HSA-MPs were taken up by A549 cells up to 98% and localized in the cell lysosomal compartment. This study suggests that DOX-HSA-MPs which was fabricated by CCD technique is seen as a promising biopolymer particle as well as a viable alternative for drug delivery application to use for cancer therapy. |
| first_indexed | 2024-04-11T12:42:05Z |
| format | Article |
| id | doaj.art-7cecbc9c9d3c4567adcbf503c17351b4 |
| institution | Directory Open Access Journal |
| issn | 1999-4923 |
| language | English |
| last_indexed | 2024-04-11T12:42:05Z |
| publishDate | 2020-03-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pharmaceutics |
| spelling | doaj.art-7cecbc9c9d3c4567adcbf503c17351b42022-12-22T04:23:28ZengMDPI AGPharmaceutics1999-49232020-03-0112322410.3390/pharmaceutics12030224pharmaceutics12030224Doxorubicin–Loaded Human Serum Albumin Submicron Particles: Preparation, Characterization and In Vitro Cellular UptakeSaranya Chaiwaree0Ausanai Prapan1Nittiya Suwannasom2Tomás Laporte3Tanja Neumann4Axel Pruß5Radostina Georgieva6Hans Bäumler7Institute of Transfusion Medicine, Charité-Universitätsmedizin Berlin, 10117 Berlin, GermanyInstitute of Transfusion Medicine, Charité-Universitätsmedizin Berlin, 10117 Berlin, GermanyInstitute of Transfusion Medicine, Charité-Universitätsmedizin Berlin, 10117 Berlin, GermanyInstitute of Transfusion Medicine, Charité-Universitätsmedizin Berlin, 10117 Berlin, GermanyJPK BioAFM Business, Nano Surfaces Division, Bruker Nano GmbH, 12489 Berlin, GermanyInstitute of Transfusion Medicine, Charité-Universitätsmedizin Berlin, 10117 Berlin, GermanyInstitute of Transfusion Medicine, Charité-Universitätsmedizin Berlin, 10117 Berlin, GermanyInstitute of Transfusion Medicine, Charité-Universitätsmedizin Berlin, 10117 Berlin, GermanyDoxorubicin (DOX) is an effective anthracycline antibiotic drug which is commonly used in a broad range cancer therapy. However, due to dose depending side effects and toxicity to non-cancerous tissues, its clinical applications are restricted. To overcome these limitations, human serum albumin (HSA) has been investigated as a biocompatible drug delivery vehicle. In this study, human serum albumin submicron particles (HSA-MPs) were fabricated by using the Co-precipitation–Crosslinking–Dissolution technique (CCD technique) and DOX was loaded into the protein particles by absorption. DOX-HSA-MPs showed uniform peanut-like shape, submicron size and negative zeta-potential (−13 mV). The DOX entrapment efficiency was 25% of the initial amount. The in vitro release in phosphate buffered saline pH 7.4 was less than 1% within 5 h. In contrast, up to 40% of the entrapped DOX was released in presence of a protein digesting enzyme mixture (Pronase<sup>®</sup>) within the same time. In addition, in vitro cytotoxicity and cellular uptake of DOX-HSA-MPs were evaluated using the lung carcinoma cell line A549. The results demonstrated that DOX-HSA-MPs reduced the cell metabolic activities after 72 h. Interestingly, DOX-HSA-MPs were taken up by A549 cells up to 98% and localized in the cell lysosomal compartment. This study suggests that DOX-HSA-MPs which was fabricated by CCD technique is seen as a promising biopolymer particle as well as a viable alternative for drug delivery application to use for cancer therapy.https://www.mdpi.com/1999-4923/12/3/224doxorubicinalbumin particlesccd techniquecellular uptakesubmicron particles |
| spellingShingle | Saranya Chaiwaree Ausanai Prapan Nittiya Suwannasom Tomás Laporte Tanja Neumann Axel Pruß Radostina Georgieva Hans Bäumler Doxorubicin–Loaded Human Serum Albumin Submicron Particles: Preparation, Characterization and In Vitro Cellular Uptake Pharmaceutics doxorubicin albumin particles ccd technique cellular uptake submicron particles |
| title | Doxorubicin–Loaded Human Serum Albumin Submicron Particles: Preparation, Characterization and In Vitro Cellular Uptake |
| title_full | Doxorubicin–Loaded Human Serum Albumin Submicron Particles: Preparation, Characterization and In Vitro Cellular Uptake |
| title_fullStr | Doxorubicin–Loaded Human Serum Albumin Submicron Particles: Preparation, Characterization and In Vitro Cellular Uptake |
| title_full_unstemmed | Doxorubicin–Loaded Human Serum Albumin Submicron Particles: Preparation, Characterization and In Vitro Cellular Uptake |
| title_short | Doxorubicin–Loaded Human Serum Albumin Submicron Particles: Preparation, Characterization and In Vitro Cellular Uptake |
| title_sort | doxorubicin loaded human serum albumin submicron particles preparation characterization and in vitro cellular uptake |
| topic | doxorubicin albumin particles ccd technique cellular uptake submicron particles |
| url | https://www.mdpi.com/1999-4923/12/3/224 |
| work_keys_str_mv | AT saranyachaiwaree doxorubicinloadedhumanserumalbuminsubmicronparticlespreparationcharacterizationandinvitrocellularuptake AT ausanaiprapan doxorubicinloadedhumanserumalbuminsubmicronparticlespreparationcharacterizationandinvitrocellularuptake AT nittiyasuwannasom doxorubicinloadedhumanserumalbuminsubmicronparticlespreparationcharacterizationandinvitrocellularuptake AT tomaslaporte doxorubicinloadedhumanserumalbuminsubmicronparticlespreparationcharacterizationandinvitrocellularuptake AT tanjaneumann doxorubicinloadedhumanserumalbuminsubmicronparticlespreparationcharacterizationandinvitrocellularuptake AT axelpruß doxorubicinloadedhumanserumalbuminsubmicronparticlespreparationcharacterizationandinvitrocellularuptake AT radostinageorgieva doxorubicinloadedhumanserumalbuminsubmicronparticlespreparationcharacterizationandinvitrocellularuptake AT hansbaumler doxorubicinloadedhumanserumalbuminsubmicronparticlespreparationcharacterizationandinvitrocellularuptake |